Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.66 |
| ▸ | ESRRB | O95718 | 4/20 | 0.62 |
| ▸ | ESR1 | P03372 | 8/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534161 | 0.82 | ESRRB (0.64) | CYP19A1ESRRBESR1ESR2MEN1 | |
| SCHEMBL639037 | 0.81 | ESRRB (0.77) | CYP19A1ESRRBESR1ESR2MEN1 | |
| SCHEMBL639038 | 0.81 | ESRRB (0.77) | CYP19A1ESRRBESR1ESR2MEN1 | |
| SCHEMBL24688923 | 0.80 | ESRRG (0.65) | CYP19A1ESRRBESR1MAPT | |
| SCHEMBL10016265 | 0.79 | ESRRB (1.00) | CYP19A1ESRRBESR1ESR2MEN1 | |
| SCHEMBL10047996 | 0.79 | ESRRB (1.00) | CYP19A1ESRRBESR1ESR2MEN1 | |
| SCHEMBL24688914 | 0.78 | ESRRG (0.66) | CYP19A1ESRRBESR1 | |
| SCHEMBL68101 | 0.78 | ESR1 (0.70) | CYP19A1ESRRBESR1ESR2CES2 | |
| SCHEMBL68100 | 0.78 | ESR1 (0.70) | CYP19A1ESRRBESR1ESR2CES2 | |
| SCHEMBL9891113 | 0.78 | ESR1 (0.70) | CYP19A1ESRRBESR1ESR2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119695-B2 | Compounds and methods for treating breast cancer and other diseases | CITY OF HOPE (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119695-B2 | Compounds and methods for treating breast cancer and other diseases | CITY OF HOPE (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090176305-A1 | COMPOUNDS AND METHODS FOR TREATING BREAST CANCER AND OTHER DISEASES | CITY OF HOPE | 2009-07-09 | — | — | US | disclosed |
| US-20090176305-A1 | COMPOUNDS AND METHODS FOR TREATING BREAST CANCER AND OTHER DISEASES | CITY OF HOPE | 2009-07-09 | — | — | US | disclosed |
| US-7531578-B2 | Acetic acid 4-{1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester; estrogen related receptor (ERR beta or ERR gamma) antagonist; thirty times more effective than 4-hydroxytamoxifen | CITY OF HOPE (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531578-B2 | Acetic acid 4-{1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester; estrogen related receptor (ERR beta or ERR gamma) antagonist; thirty times more effective than 4-hydroxytamoxifen | CITY OF HOPE (US) | 2009-05-12 | — | — | US | disclosed |